ResMed |
RMD · Health Care Equipment
$252.86
0.1%Steris
STE · Health Care Equipment
$232.15
0.0%The short version
- Steris is the larger business, with $5.9B of revenue in fiscal 2026 against $5.7B for ResMed |.
- ResMed | grew revenue faster (9.9%, against 8.7%).
- ResMed | kept more of each dollar of sales as operating profit (33.4% operating margin, against 18.6% operating margin).
- ResMed | turned more of its sales into free cash flow (29.2% FCF margin, against 16.4% FCF margin).
- ResMed | earned a higher return on the capital invested in it (26.7%, against 9.6%).
- Investors pay more for each dollar of Steris’s earnings: a P/E of 28.4x against 24.2x for ResMed |.
| Latest fiscal year | RMD · FY26 | STE · FY26 |
|---|---|---|
| Size | ||
| Market cap | $36.9B | $22.7B |
| Revenue | $5.7B | $5.9B |
| Free cash flow | $1.6B | $972M |
| Net income | $1.5B | $782M |
| Growth | ||
| Revenue growth | 9.9% | 8.7% |
| 5-year growth | 12.1% | 13.8% |
| Share count change | −0.9% | −0.4% |
| Profitability | ||
| Gross margin | 61.1% | 44.3% |
| Operating margin | 33.4% | 18.6% |
| Net margin | 26.9% | 13.2% |
| FCF margin | 29.2% | 16.4% |
| Return on capital | 26.7% | 9.6% |
| Return on equity | 24.3% | 11.4% |
| Balance sheet | ||
| Net debt | −$810M | $1.5B |
| Net debt / EBITDA | −0.4x | 0.9x |
| Dividends and buybacks | $1.0B | $477M |
| Valuation & quality | ||
| P/E | 24.2x | 28.4x |
| Piotroski F-score | 6 | 9 |
FY17
RMD $2.1B
STE $2.6B
FY18
RMD $2.3B
STE $2.6B
FY19
RMD $2.6B
STE $2.8B
FY20
RMD $3.0B
STE $3.0B
FY21
RMD $3.2B
STE $3.1B
FY22
RMD $3.6B
STE $4.2B
FY23
RMD $4.2B
STE $4.5B
FY24
RMD $4.7B
STE $5.1B
FY25
RMD $5.1B
STE $5.5B
FY26
RMD $5.7B
STE $5.9B
RMD
STE
FY17
RMD 20.6%
STE 8.7%
FY18
RMD 23.2%
STE 15.3%
FY19
RMD 22.2%
STE 14.8%
FY20
RMD 27.4%
STE 17.7%
FY21
RMD 28.3%
STE 17.7%
FY22
RMD 28.0%
STE 11.3%
FY23
RMD 26.8%
STE 17.4%
FY24
RMD 28.2%
STE 16.3%
FY25
RMD 32.8%
STE 15.9%
FY26
RMD 33.4%
STE 18.6%
RMD
STE
FY17
RMD $352M
STE $251M
FY18
RMD $442M
STE $292M
FY19
RMD $390M
STE $350M
FY20
RMD $707M
STE $376M
FY21
RMD $634M
STE $450M
FY22
RMD $216M
STE $397M
FY23
RMD $574M
STE $395M
FY24
RMD $1.3B
STE $613M
FY25
RMD $1.7B
STE $778M
FY26
RMD $1.6B
STE $972M
RMD
STE
FY17
RMD —
STE —
FY18
RMD —
STE —
FY19
RMD 16.9%
STE 8.0%
FY20
RMD 21.4%
STE 10.5%
FY21
RMD 15.0%
STE 8.8%
FY22
RMD 22.8%
STE 5.1%
FY23
RMD 20.0%
STE 7.1%
FY24
RMD 20.0%
STE 7.2%
FY25
RMD 26.2%
STE 7.5%
FY26
RMD 26.7%
STE 9.6%
RMD
STE
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.